Testing a Probiotic for ME/CFS, With or Without Irritable Bowel Syndrome
Tests a probiotic against placebo in adults aged 45 to 70 with ME/CFS.
Key facts
- Who runs it
- Nova Southeastern University
- Where
- Fort Lauderdale, United StatesSee the site
- Trial code
- Registry title
- The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 100 people, planned
- Started
- 20 Dec 2022
- Planned end
- 24 Feb 2026
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Floradapt Intensive GI
- Placebo
- Record updated
- 4 March 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 45 to 70 with ME/CFS, with or without irritable bowel syndrome (IBS). Half of the people will have IBS too.
- Age
- 45 to 70 years
- Sex
- All sexes can join.
- Disease stage
- ME/CFS that meets the IOM (Canadian Consensus) case definition. Some people also have alternating or diarrhea-predominant IBS (Rome IV criteria).
- Earlier treatment
- No probiotics and no antibiotics in the past eight weeks.
Main reasons for not taking part
- Pregnant or breastfeeding women
- Probiotics or antibiotics in the past eight weeks
- Short bowel syndrome, celiac disease, biliary disease, pancreatitis, or inflammatory bowel disease (Crohn's disease, ulcerative colitis)
- Severe heart or nervous system condition, or liver failure
- Gastrointestinal surgery within six months, or a history of psychiatric disorder, alcohol or illicit drug abuse
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Meets IOM ME/CFS case definition criteria,
- Co-morbid IBS: meets RomeIV criteria for alternating or diarrhea-predominant IBS as reported during screening (technically diagnosed by a physician),
- Able to provide consent to study,
- Patients of childbearing potential must practice effective contraception during the study and be willing to continue contraception for at least six months after the intervention,
- agrees to participate in online surveys and follow-up visits
Who cannot take part
- Gastrointestinal surgery within six months of study entry,
- Medical conditions including short bowel syndrome, celiac disease, biliary disease, pancreatitis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), severe cardiovascular, neurological condition, or liver failure,
- History of psychiatric disorder, alcohol or illicit drug abuse
- Probiotics in the past eight weeks,
- Antibiotics in the past eight weeks,
- Pregnancy or lactating women,
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 45 and 70 years old?
Where in United States
- Institute for Neuroimmune MedicineFort Lauderdale, United StatesContact: Oleksandra ShchebetTaking people
About the trial
What the trial wants to find out
This clinical study aims to evaluate the use of i3.1 probiotic in participants who meet the Institute of Medicine (Canadian Consensus Criteria) case definition for ME/CFS and who may or may not be diagnosed with irritable bowel syndrome (IBS). The main questions it aims to answer are:
Read full original descriptionShow less
* how effective is the usage of the i3.1 probiotic to reduce gastrointestinal (GI) inflammation and normalize the GI and systemic/brain interface? * how well is it working on IBS severity? The study sample is 100 male and female participants aged 45 to 70 years with ME/CFS (per the Canadian Consensus Criteria); one-half of the participants will have co-morbid IBS (per Rome IV criteria). Participants will receive an i3.1 or a placebo and be assessed at baseline, at eight weeks, and at 12 weeks (four weeks post-treatment completion).
The 4 groups in the trial
- Individuals with ME/CFS with IBS on active medicationExisting treatment, for comparison
Individuals with ME/CFS with IBS take Floradapt Intensive GI (another name i3.1), one high dose capsule (\>3x10 to the ninth power) once daily for eight weeks.
Treatment: Floradapt Intensive GI
- Individuals with ME/CFS with IBS on placeboPlacebo, for comparison
Individuals with ME/CFS with IBS take a placebo, one capsule once daily for eight weeks.
Treatment: Placebo
- Individuals with ME/CFS without IBS on active medicationExisting treatment, for comparison
Individuals with ME/CFS without IBS take Floradapt Intensive GI (another name i3.1), one high dose capsule (\>3x10 to the ninth power) once daily for eight weeks.
Treatment: Floradapt Intensive GI
- Individuals with ME/CFS without IBS on placeboPlacebo, for comparison
Individuals with ME/CFS without IBS take a placebo, one capsule once daily for eight weeks.
Treatment: Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
- Plain-language title
- Testing a Probiotic for ME/CFS, With or Without Irritable Bowel SyndromeGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06211062, who can take part
- Record updated
- 4 March 2025